Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01811732 · ClinicalTrials.gov registry record · Phase 3
Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
A Phase 3 study, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 660
- Enrollment target
NCT01811732 is a Phase 3 study that has completed, run by Melinta Therapeutics. The registered enrollment target is 660 participants.
The verdict
NCT01811732, a Phase 3 study, has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 660 participants
- Enrollment target
Study Summary
This study was designed to evaluate the efficacy of delafloxacin patients with acute bacterial skin and soft tissue infections (ABSSSI).
Interventions
- DRUG Placebo
- DRUG Vancomycin
- DRUG Aztreonam
- DRUG Delafloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01811732
The ClinicalTrials.gov registry entry for NCT01811732 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 660 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01811732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01811732 about?
NCT01811732 is a clinical study titled "Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections". This study was designed to evaluate the efficacy of delafloxacin patients with acute bacterial skin and soft tissue infections (ABSSSI).
What is the current status of trial NCT01811732?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 660 participants. The study started on 2013-04. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01811732?
The interventions under investigation include: Placebo (DRUG), Vancomycin (DRUG), Aztreonam (DRUG), Delafloxacin (DRUG).
Who is sponsoring clinical trial NCT01811732?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.